Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia | MicrobiomeTrials← Back to trialsNCT07714070
Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia
RecruitingPHASE2INTERVENTIONAL
Trial Details
Start: 2026-07Est. Completion: 2027-09
Enrollment target: 48 participants Locations- Peking University People's Hospital, Beijing, Beijing Municipality, China
Other microbiome trials you might be interested in
Endometrial AdenocarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Mucinous AdenocarcinomaEndometrial Undifferentiated CarcinomaEndometrioid AdenocarcinomaRecurrent Endometrial Carcinoma
This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink t…
Birmingham, United StatesEst. completion Jul 30, 2032
Phase 3
Recruiting
Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that…
Mobile, United StatesEst. completion May 24, 2032
Endometrial CarcinomaEndometrial Clear Cell AdenocarcinomaEndometrial Dedifferentiated CarcinomaEndometrial Endometrioid AdenocarcinomaEndometrial Mixed Cell AdenocarcinomaEndometrial Serous AdenocarcinomaEndometrial Undifferentiated CarcinomaUterine Corpus Malignant Mixed Mesodermal (Mullerian) Tumor
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, t…
Birmingham, United StatesEst. completion Oct 31, 2027